nach oben

Erschienen in:

01.07.2007 | Original Article

Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum

verfasst von: Guanglin Cui, Rasmus Goll, Trine Olsen, Sonja Eriksson Steigen, Anne Husebekk, Barthold Vonen, Jon Florholmen

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Cytokines have been suggested to be key factors in modulating immune response against tumorigenesis in the microenvironment. Therefore, characterization of cytokine expression along the colorectal adenoma–carcinoma sequence may add important information for understanding the immune-related mechanisms of the development of colorectal carcinoma (CRC). In this study, biopsies from 32 patients with colorectal adenoma (CRA), 20 patients with CRC and 18 healthy controls were examined. Cytokine gene expressions of interleukin-4 (IL-4), IL-10, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and its upstream inducers (IL-12A and IL-18) were measured at messenger RNA (mRNA) level with quantitative real-time PCR (Q-PCR). Cytokine expressing cells were characterized using immunohistochemistry (IHC). A distinct different cytokine profile between adenoma and CRC was observed: the Th1 cytokines (IFN-gamma, TNF-alpha, IL-12A and IL-18) were increased in local tissues of CRA and decreased in CRC. Consistent with the quantitative cytokine data, IHC examinations revealed slightly increased densities of Th1 cytokine-expressing cells in CRA and a remarkably decreased density of the Th1 cells in CRC. In CRA, the cytokine-expressing cells were highly polarized to the subepithelial stroma while the cells were evenly distributed through the stroma in CRC. In conclusion, distinct changes in the Th1 cytokine profile appear along the colorectal adenoma–carcinoma sequence. This may reflect a change in the host immune regulatory function in the adenoma–carcinoma sequence.

Leslie A, Carey FA, Pratt NR, Steele RJ (2002) The colorectal adenoma–carcinoma sequence. Br J Surg 89:845–860PubMedCrossRef

Zhang L, Zhou W, Velculescu VE et al (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272PubMedCrossRef

Whiteside TL (2006) The role of immune cells in the tumor microenvironment. Cancer Treat Res 130:103–124PubMedCrossRef

Schottelius AJ, Dinter H (2006) Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 130:67–87PubMed

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148PubMedCrossRef

O’Connell J, Bennett MW, Nally K, Houston A, O’Sullivan GC, Shanahan F (2000) Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor–immune conflict. Ann NY Acad Sci 910:178–192; discussion 193–175

Naito Y, Saito K, Shiiba K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494PubMed

Coca S, Perez-Piqueras J, Martinez D et al (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:2320–2328PubMedCrossRef

Chiba T, Ohtani H, Mizoi T et al (2004) Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 91:1711–1717PubMed

10.

Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G (2003) Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 46:33–57PubMed

11.

Banner BF, Sonmez-Alpan E, Yousem SA (1993) An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Mod Pathol 6:295–301PubMed

12.

Banner BF, Savas L, Baker S, Woda BA (1993) Characterization of the inflammatory cell populations in normal colon and colonic carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 64:213–220PubMedCrossRef

13.

Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside TL (1990) Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 98:259–268PubMed

14.

Contasta I, Berghella AM, Pellegrini P, Adorno D (2003) Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 18:549–557PubMedCrossRef

15.

Berghella AM, Pellegrini P, Del Beato T et al (1998) The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 45:241–249PubMedCrossRef

16.

Berghella AM, Pellegrini P, Piancatelli D et al (1994) Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother 38:160–166PubMed

17.

Barth RJ Jr, Camp BJ, Martuscello TA, Dain BJ, Memoli VA (1996) The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer 78:1168–1178PubMedCrossRef

18.

Naylor MS, Stamp GW, Balkwill FR (1990) Investigation of cytokine gene expression in human colorectal cancer. Cancer Res 50:4436–4440PubMed

19.

Csiszar A, Szentes T, Haraszti B, Balazs A, Petranyi GG, Pocsik E (2004) The pattern of cytokine gene expression in human colorectal carcinoma. Pathol Oncol Res 10:109–116PubMedCrossRef

20.

Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1–8PubMedCrossRef

21.

Baier PK, Wolff-Vorbeck G, Eggstein S, Baumgartner U, Hopt UT (2005) Cytokine expression in colon carcinoma. Anticancer Res 25:2135–2139PubMed

22.

Pages F, Vives V, Sautes-Fridman C et al (1999) Control of tumor development by intratumoral cytokines. Immunol Lett 68:135–139PubMedCrossRef

23.

Shibata M, Nezu T, Kanou H, Abe H, Takekawa M, Fukuzawa M (2002) Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 34:416–420PubMedCrossRef

24.

Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82:1009–1012PubMedCrossRef

25.

Chung YC, Chang YF (2003) Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 50:1910–1913PubMed

26.

Matsuo K, Oka M, Murase K et al (2003) Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J Int Med Res 31:69–75PubMed

27.

Piancatelli D, Romano P, Sebastiani P, Adorno D, Casciani CU (1999) Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother 22:25–32PubMedCrossRef

28.

Becker C, Fantini MC, Wirtz S et al (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220PubMed

29.

Galizia G, Orditura M, Romano C et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178PubMedCrossRef

30.

Kinoshita T, Ito H, Miki C (1999) Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85:2526–2531PubMedCrossRef

31.

Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R (2006) Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 66:249–259PubMedCrossRef

32.

Cui G, Koh TJ, Chen D et al (2004) Overexpression of glycine-extended gastrin inhibits parietal cell loss and atrophy in the mouse stomach. Cancer Res 64:8160–8166PubMedCrossRef

33.

O’Hara RJ, Greenman J, Drew PJ et al (1998) Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer. Dis Colon Rectum 41:460–463PubMedCrossRef

34.

Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155–168PubMedCrossRef

35.

Nishimura T, Nakui M, Sato M et al (2000) The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46 46 (Suppl): S52–S61CrossRef

36.

Bosco MC, Pulkki K, Rowe TK et al (1995) IL-4 inhibits IL-2-induced tumoricidal activity and secretory functions of human monocytes. Modulation of IL-2 binding and IL-2 receptor beta gamma chain expression. J Immunol 155:1411–1419PubMed

37.

Osawa E, Nakajima A, Fujisawa T et al (2005) Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer 118:2232–2236CrossRef

38.

Romagnani S (1999) Th1/Th2 cells. Inflamm Bowel Dis 5:285–294PubMedCrossRef

39.

Negus RP, Balkwill FR (1996) Cytokines in tumour growth, migration and metastasis. World J Urol 14:157–165PubMedCrossRef

40.

Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13:135–141PubMedCrossRef

41.

Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86:231–245PubMedCrossRef

42.

Brigati C, Noonan DM, Albini A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19:247–258PubMedCrossRef

43.

Pages F, Berger A, Lebel-Binay S et al (2000) Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett 75:9–14PubMedCrossRef

44.

Tanaka S, Tatsuguchi A, Futagami S et al (2006) Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 55:54–61PubMedCrossRef

45.

Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, Powell DW (2004) Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 10:5870–5879PubMedCrossRef

46.

Vila-del Sol V, Fresno M (2005) Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages. J Immunol 174:2825–2833PubMed

47.

Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD, Powell DW (2002) Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 282: C824–C834PubMed

48.

Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Tanaka H, Isobe M (2006) A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 40:688–695PubMedCrossRef

49.

Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D (1999) Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 28:29–41PubMed

Titel: Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum
verfasst von: Guanglin Cui
Rasmus Goll
Trine Olsen
Sonja Eriksson Steigen
Anne Husebekk
Barthold Vonen
Jon Florholmen
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0259-y

Springer Medizin

Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma

Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients

Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie